Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Rating of “Moderate Buy” from Analysts

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $10.80.

RGLS has been the subject of a number of recent analyst reports. Oppenheimer reiterated an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a report on Wednesday, August 14th. Canaccord Genuity Group lifted their target price on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Friday, August 9th. Finally, StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a research report on Friday.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. increased its position in shares of Regulus Therapeutics by 16.5% during the fourth quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after acquiring an additional 38,529 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 42,600 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Regulus Therapeutics in the second quarter worth approximately $136,000. Opaleye Management Inc. bought a new position in shares of Regulus Therapeutics in the first quarter valued at approximately $490,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Regulus Therapeutics during the second quarter valued at approximately $352,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Stock Down 6.4 %

NASDAQ RGLS opened at $1.46 on Monday. The company has a market capitalization of $95.59 million, a price-to-earnings ratio of -1.00 and a beta of 1.63. Regulus Therapeutics has a twelve month low of $1.08 and a twelve month high of $3.79. The stock has a fifty day simple moving average of $1.67 and a 200 day simple moving average of $2.04.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.17). Research analysts expect that Regulus Therapeutics will post -0.8 earnings per share for the current fiscal year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.